Prokineticin 2 and Prokineticin Receptor 2 as a Target to Treat Epilepsy and Seizures

Tech ID: 18757 / UC Case 2007-293-0

Background

PK2 belongs to a family of secreted peptides that regulate diverse biological functions including serving as a regulatory molecule for circadian rhythms. The signaling of PK2 is mediated through two cognate G-protein coupled receptors Prokineticin Receptor 1 and Prokineticin Receptor 2 (PKR1 and PKR2).

Technology Description

Researchers at the University of California have found that PK2 is an important regulator of seizure onset and epilepsy. A PKR2 modulator would thus help treat epileptic patients and/or patients suffering from non-epileptic seizures. Certain materials such as cDNAs and cell lines that may be used as screening and research tools are readily available for licensing. This technology is also available for sponsor research opportunities.

Applications

Patent Status

Country Type Number Dated Case
United States Of America Issued Patent 8,101,158 01/24/2012 2007-293
 

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information

Categorized As

  • AN INTEGRAL PART OF
  • Institute for Innovation Logo
  • Institute for Innovation Logo

University of California, Irvine Invention Transfer Group
5141 California Avenue, Suite 200, Irvine,CA 92697-7700
Tel: 949.824.2683 | Fax: 949.824.3880
www.ota.uci.edu | ota@uci.edu

© 2009 - 2016, The Regents of the University of California
Terms of use | Privacy Notice